Table 3.

Upcoming loss of exclusivity for biologic agents widely used in oncology

Biologic agent	Clinical setting	Mechanism of action	Loss of exclusivity US, year	Loss of exclusivity EU, year
Trastuzumab	HER2-overexpressing breast and gastric cancer	HER2-targeted mAb	2019	2014
Rituximab	Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia	CD20-targeted mAb	2017	2014
Bevacizumab	Non-small cell lung cancer, colorectal cancer	VEGF-targeted angiogenesis inhibitor	2019	2020
Cetuximab	Head and neck cancer, colorectal cancer	EGFR inhibitor (mAb)	2016	2016

Abbreviations: mAb, monoclonal antibody; EGFR, epidermal growth factor receptor; US, United States; HER2, human epidermal growth factor 2; EU, European Union; VEGF, vascular endothelial growth factor.